IPP Bureau

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

By IPP Bureau - November 08, 2023

This product will be manufactured at Lupin’s Pithampur facility in India

Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr
Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr

By IPP Bureau - November 07, 2023

Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023

Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr
Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr

By IPP Bureau - November 07, 2023

Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023

Max Healthcare Institute reports Q2 FY24 consolidated PAT at Rs. 276.68 Cr
Max Healthcare Institute reports Q2 FY24 consolidated PAT at Rs. 276.68 Cr

By IPP Bureau - November 07, 2023

Max Healthcare Institute has reported total income of Rs. 1408.64 crores during the period ended September 30, 2023

Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr
Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr

By IPP Bureau - November 07, 2023

Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023

Zydus Wellness consolidated Q2 FY24 PAT drops to Rs. 5.9 Cr
Zydus Wellness consolidated Q2 FY24 PAT drops to Rs. 5.9 Cr

By IPP Bureau - November 07, 2023

Zydus Wellness has reported total income of Rs. 444 crores during the period ended September 30, 2023

Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr
Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr

By IPP Bureau - November 06, 2023

Metropolis Healthcare has reported total income of Rs. 309.71 crores during the period ended September 30, 2023

Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr
Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr

By IPP Bureau - November 06, 2023

Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023

Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr

By IPP Bureau - November 06, 2023

The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023

Poly Medicure posts consolidated Q2 FY24 PAT at Rs. 62.18 Cr
Poly Medicure posts consolidated Q2 FY24 PAT at Rs. 62.18 Cr

By IPP Bureau - November 06, 2023

Poly Medicure has reported total income of Rs. 351.38 crores during the period ended September 30, 2023

Henkel launches new medical grade wearables device light cure adhesives
Henkel launches new medical grade wearables device light cure adhesives

By IPP Bureau - November 04, 2023

The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal
Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

By IPP Bureau - November 04, 2023

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region

Lupin receives tentative approval from USFDA for Selexipag for injection
Lupin receives tentative approval from USFDA for Selexipag for injection

By IPP Bureau - November 04, 2023

This product will be manufactured at Lupin's Nagpur facility in India

Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr
Tatva Chintan Pharma Chem reports Q2 FY24 consolidated PAT at Rs. 7.78 Cr

By IPP Bureau - November 04, 2023

Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023

The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards
The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards

By IPP Bureau - November 03, 2023

In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer

Latest Stories

Interviews

Packaging